Application of glycyrrhizinic acid in treatment of patients with alcoholic liver disease

Aim of investigation. To estimate of clinical efficacy and safety profile of parenteral form of «Phosphogliv» preparation containing glycyrrhizin and essential phospholipids, at treatment of patients with alcoholic liver disease.Materials and methods. Overall 106 patients with chronic alcohol-induce...

Full description

Saved in:
Bibliographic Details
Main Authors: I. G. Nikitin, I. Ye. Baykova, V. M. Volynkina, L. M. Gogova, G. I. Storozhakov, M. P. Prushkovskaya
Format: Article
Language:Russian
Published: Gastro LLC 2009-02-01
Series:Российский журнал гастроэнтерологии, гепатологии, колопроктологии
Subjects:
Online Access:https://www.gastro-j.ru/jour/article/view/1602
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1823860257832566784
author I. G. Nikitin
I. Ye. Baykova
V. M. Volynkina
L. M. Gogova
G. I. Storozhakov
M. P. Prushkovskaya
author_facet I. G. Nikitin
I. Ye. Baykova
V. M. Volynkina
L. M. Gogova
G. I. Storozhakov
M. P. Prushkovskaya
author_sort I. G. Nikitin
collection DOAJ
description Aim of investigation. To estimate of clinical efficacy and safety profile of parenteral form of «Phosphogliv» preparation containing glycyrrhizin and essential phospholipids, at treatment of patients with alcoholic liver disease.Materials and methods. Overall 106 patients with chronic alcohol-induced liver diseases were investigated, diagnosis was verified by standard methods with obligatory assessment of the expert in narcology. Patients were randomized by random sample method in two groups: I group (n=58) – an abstinence in combination to placebo (intravenous injection 20 ml of normal saline solution 2 times per week), II group (n=48) – abstinence in combination to intravenous injection of 2,5 g of phosphogliv 2 times per week. Total period of observation was 104–106 wks on the average. Basic biochemical parameters, liver morphology and data of US-investigation were estimated.Results. Before treatment the level of transaminases was: ALT 89,3±12,9 IU/l and AST 124,3±26,7 IU/l (I group), 78,2±23,8 and 135,6±37,3 IU/l respectively (II group). On the 52-nd week levels of transaminases essentially differed: ALT level at patients of the I group became 84,6±10,4, at patients of II group – 39,7±12,5 IU/l, AST – respectively 96,6±11,7 and 63,2±9,6 IU/l (p<0,01). The level of tumor necrosis factor-α significantly differed and was equal to 796,8±89,9 mcmol/l in patients receiving placebo, and 412,8±76,8 mcmol/l in group, receiving glycyrrhizinic acid (p><0,01). Conclusion. Application of phosphogliv along with abstinence increases efficacy of therapy of alcoholinduced liver disease. The further studying of this agent is necessary at various clinical variants of disease with dynamic evaluation of basic clinical and laboratory parameters and effects of treatment on liver morphology.>< 0,01). The level of tumor necrosis factor-α significantly differed and was equal to 796,8±89,9 mcmol/l in patients receiving placebo, and 412,8±76,8 mcmol/l in group, receiving glycyrrhizinic acid (p< 0,01).Conclusion. Application of phosphogliv along with abstinence increases efficacy of therapy of alcoholinduced liver disease. The further studying of this agent is necessary at various clinical variants of disease with dynamic evaluation of basic clinical and laboratory parameters and effects of treatment on liver morphology.
format Article
id doaj-art-1e157b7546104f97af82104800d5272c
institution Kabale University
issn 1382-4376
2658-6673
language Russian
publishDate 2009-02-01
publisher Gastro LLC
record_format Article
series Российский журнал гастроэнтерологии, гепатологии, колопроктологии
spelling doaj-art-1e157b7546104f97af82104800d5272c2025-02-10T16:14:30ZrusGastro LLCРоссийский журнал гастроэнтерологии, гепатологии, колопроктологии1382-43762658-66732009-02-0119153581107Application of glycyrrhizinic acid in treatment of patients with alcoholic liver diseaseI. G. NikitinI. Ye. BaykovaV. M. VolynkinaL. M. GogovaG. I. StorozhakovM. P. PrushkovskayaAim of investigation. To estimate of clinical efficacy and safety profile of parenteral form of «Phosphogliv» preparation containing glycyrrhizin and essential phospholipids, at treatment of patients with alcoholic liver disease.Materials and methods. Overall 106 patients with chronic alcohol-induced liver diseases were investigated, diagnosis was verified by standard methods with obligatory assessment of the expert in narcology. Patients were randomized by random sample method in two groups: I group (n=58) – an abstinence in combination to placebo (intravenous injection 20 ml of normal saline solution 2 times per week), II group (n=48) – abstinence in combination to intravenous injection of 2,5 g of phosphogliv 2 times per week. Total period of observation was 104–106 wks on the average. Basic biochemical parameters, liver morphology and data of US-investigation were estimated.Results. Before treatment the level of transaminases was: ALT 89,3±12,9 IU/l and AST 124,3±26,7 IU/l (I group), 78,2±23,8 and 135,6±37,3 IU/l respectively (II group). On the 52-nd week levels of transaminases essentially differed: ALT level at patients of the I group became 84,6±10,4, at patients of II group – 39,7±12,5 IU/l, AST – respectively 96,6±11,7 and 63,2±9,6 IU/l (p<0,01). The level of tumor necrosis factor-α significantly differed and was equal to 796,8±89,9 mcmol/l in patients receiving placebo, and 412,8±76,8 mcmol/l in group, receiving glycyrrhizinic acid (p><0,01). Conclusion. Application of phosphogliv along with abstinence increases efficacy of therapy of alcoholinduced liver disease. The further studying of this agent is necessary at various clinical variants of disease with dynamic evaluation of basic clinical and laboratory parameters and effects of treatment on liver morphology.>< 0,01). The level of tumor necrosis factor-α significantly differed and was equal to 796,8±89,9 mcmol/l in patients receiving placebo, and 412,8±76,8 mcmol/l in group, receiving glycyrrhizinic acid (p< 0,01).Conclusion. Application of phosphogliv along with abstinence increases efficacy of therapy of alcoholinduced liver disease. The further studying of this agent is necessary at various clinical variants of disease with dynamic evaluation of basic clinical and laboratory parameters and effects of treatment on liver morphology.https://www.gastro-j.ru/jour/article/view/1602alcohol-induced liver diseasetumor necrosis factor-αtransaminasesbilirubinabstinence
spellingShingle I. G. Nikitin
I. Ye. Baykova
V. M. Volynkina
L. M. Gogova
G. I. Storozhakov
M. P. Prushkovskaya
Application of glycyrrhizinic acid in treatment of patients with alcoholic liver disease
Российский журнал гастроэнтерологии, гепатологии, колопроктологии
alcohol-induced liver disease
tumor necrosis factor-α
transaminases
bilirubin
abstinence
title Application of glycyrrhizinic acid in treatment of patients with alcoholic liver disease
title_full Application of glycyrrhizinic acid in treatment of patients with alcoholic liver disease
title_fullStr Application of glycyrrhizinic acid in treatment of patients with alcoholic liver disease
title_full_unstemmed Application of glycyrrhizinic acid in treatment of patients with alcoholic liver disease
title_short Application of glycyrrhizinic acid in treatment of patients with alcoholic liver disease
title_sort application of glycyrrhizinic acid in treatment of patients with alcoholic liver disease
topic alcohol-induced liver disease
tumor necrosis factor-α
transaminases
bilirubin
abstinence
url https://www.gastro-j.ru/jour/article/view/1602
work_keys_str_mv AT ignikitin applicationofglycyrrhizinicacidintreatmentofpatientswithalcoholicliverdisease
AT iyebaykova applicationofglycyrrhizinicacidintreatmentofpatientswithalcoholicliverdisease
AT vmvolynkina applicationofglycyrrhizinicacidintreatmentofpatientswithalcoholicliverdisease
AT lmgogova applicationofglycyrrhizinicacidintreatmentofpatientswithalcoholicliverdisease
AT gistorozhakov applicationofglycyrrhizinicacidintreatmentofpatientswithalcoholicliverdisease
AT mpprushkovskaya applicationofglycyrrhizinicacidintreatmentofpatientswithalcoholicliverdisease